Physician profile
Hugo Rams, JR.
NPI 1053388272
$5,277.82
in general payments reported to CMS, 2019-2025
20 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $809 · 2021: $966 · 2022: $706 · 2023: $561 · 2024: $544 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,051.10 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $695.85 | 2020-2025 | |
| Nestle Healthcare Nutrition INC. | $472.67 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $359.32 | 2019-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $305.54 | 2019-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $257.85 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $209.92 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $184.13 | 2019-2021 | |
| Madrigal Pharmaceuticals | $179.52 | 2025 | Rezdiffra |
| Allergan, INC. | $151.90 | 2019-2020 | |
| Pfizer INC. | $102.30 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $90.69 | 2019-2022 | |
| Shionogi INC | $62.66 | 2019-2020 | |
| Braintree Laboratories, INC. | $28.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $28.03 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $26.40 | 2019 | |
| Perspectum Diagnostics LTD | $25.93 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.26 | 2024 | Iqirvo |
| Celgene Corporation | $14.39 | 2022 | |
| Redhill Biopharma INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Rams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.